Arcus Biosciences Revenue 2017-2022 | RCUS

Arcus Biosciences revenue from 2017 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Arcus Biosciences Annual Revenue
(Millions of US $)
2021 $383
2020 $78
2019 $15
2018 $8
2017 $1
2016 $
Arcus Biosciences Quarterly Revenue
(Millions of US $)
2022-06-30 $27
2022-03-31 $18
2021-12-31 $354
2021-09-30 $9
2021-06-30 $9
2021-03-31 $9
2020-12-31 $9
2020-09-30 $65
2020-06-30 $2
2020-03-31 $2
2019-12-31 $10
2019-09-30 $2
2019-06-30 $2
2019-03-31 $2
2018-12-31 $2
2018-09-30 $4
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $0
2017-06-30
2017-03-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.941B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.052B 9.22
GSK (GSK) United Kingdom $62.454B 7.50
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.939B 16.64
Ginkgo Bioworks Holdings (DNA) United States $6.283B 0.00
Myovant Sciences (MYOV) United Kingdom $2.444B 0.00
Emergent Biosolutions (EBS) United States $1.068B 6.19
ADC Therapeutics SA (ADCT) Switzerland $0.402B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.083B 0.00
SQZ Biotechnologies (SQZ) United States $0.073B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00
Biohaven Pharmaceutical Holding (BHVN) United States $0.000B 0.00